1034022-18-8

Upstream product

• 57668-35-6 3-[3-(Benzyloxy)phenyl]-1-propanol 
• 1424-74-4 3-(3-hydroxyphenyl)propanol 
• 1034019-51-6 1-{3-[3-(benzyloxy)phenyl]propyl}-5-(diphenyl-methyl)pyridin-2(1H)-one 
• 366016-86-6 1-(benzyloxy)-3-(3-iodopropyl)benzene 
• 149505-02-2 1-benzyloxy-3-[3-(methanesulphonyloxy)propyl]-benzene 

Downstream Products

• 1034016-67-5 4-(3-{3-[5-(diphenylmethyl)-2-oxopyridin-1(2H)-yl]propyl}phenoxy)butanoic acid 
• 1034017-48-5 2-(3-{3-[5-(diphenylmethyl)-2-oxopyridin-1(2H)-yl]propyl}phenoxy)propanoic acid 
• 1356397-82-4 2-(3-{3-[5-(diphenylmethyl)-2-oxopyridin-1(2H)-yl]propyl}phenoxy)butanoic acid 
• 1034019-25-4 ethyl 4-(3-{3-[5-(diphenylmethyl)-2-oxopyridin-1(2H)-yl]propyl}phenoxy)butanoate 
• 1034020-42-2 ethyl 2-(3-{3-[5-(diphenylmethyl)-2-oxopyridin-1(2H)-yl]propyl}phenoxy)propanoate 

Relevant academic research and scientific papers

Discovery of novel and potent CRTH2 antagonists

High throughput screening of our chemical library for CRTH2 antagonists provided a lead compound 1a. Initial optimization of the lead led to the discovery of a novel, potent and orally bioavailable CRTH2 antagonist 17.